Evolve Private Wealth LLC Makes New $6.90 Million Investment in United Therapeutics Corporation $UTHR

Evolve Private Wealth LLC purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, HoldingsChannel.com reports. The fund purchased 12,735 shares of the biotechnology company’s stock, valued at approximately $6,900,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Emerald Investment Advisers LLC bought a new position in United Therapeutics during the 2nd quarter valued at approximately $5,025,000. Korea Investment CORP purchased a new position in United Therapeutics during the second quarter valued at $9,645,000. EP Wealth Advisors LLC bought a new stake in United Therapeutics in the second quarter worth $566,000. Ieq Capital LLC bought a new stake in United Therapeutics in the second quarter worth $14,143,000. Finally, Callan Family Office LLC bought a new stake in United Therapeutics in the second quarter worth $1,217,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of several analyst reports. Royal Bank Of Canada reduced their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Weiss Ratings upgraded shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $646.00.

Insiders Place Their Bets

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $170,968,483.28. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $23,631,280.08. The trade was a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 442,575 shares of company stock valued at $239,326,330 in the last quarter. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $513.12 on Friday. The stock’s 50-day simple moving average is $533.08 and its two-hundred day simple moving average is $537.36. The stock has a market capitalization of $22.01 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the company posted $6.41 EPS. As a group, equities analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.